We previously showed, in a model of BRAF mutant thyroid cancer, that HSV/BRAFi was an effective combination, further improved by the addition of ICI as triple therapy,8 and here we have further developed this approach in the more common clinical context of melanoma. This evidence concerns the gene BRAF and melanoma.